H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Immune Design (IMDZ) today and set a price target of $7.75. The company’s shares closed on Friday at $1.60, close to its 52-week low of $1.25.
“Valuation and risks to price target achievement. We reiterate our Buy rating and $7.75 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. We believe upside potential exists as the company explores additional tumor indications for G100, as well as potential Immune Design Corp. December 3, 2018 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2contribution from pipeline development.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -16.9% and a 28.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immune Design with a $6.19 average price target.
The company has a one-year high of $5.05 and a one-year low of $1.25. Currently, Immune Design has an average volume of 501.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Seattle, WA.